Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
21 April, 2021 16:45 IST
Lupin launches Penicillamine Tablets
Source: IRIS | 03 Mar, 2021, 05.43PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

 Lupin, one of the leading pharmaceutical companies in India, on March 2 announced the launch of Penicillamine Tablets USP, 250 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Penicillamine Tablets USP, 250 mg, are the generic equivalent of Depen Tablets, 250 mg, of Mylan Specialty, L.P., and indicated in the treatment of Wilson's disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.

Penicillamine Tablets USP, 250 mg (RLD: DepenĀ®) had estimated annual sales of USD 5 million in the U.S., according to IQVIA MAT December 2020 report. 

 Shares of the company gained Rs 6.25, or 0.59%, to settle  at  Rs 1,060.85.  The total volume of shares traded  was  116,553 at  the BSE (Wednesday).



 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
IDBI Capital maintains Buy on HDFC Bank with target price of Rs 1,740 - 21-Apr-2021 15:13
Prestige Estates Projects acquires stake in two partnership firm - 21-Apr-2021 14:55
Jubilant Pharmova arm completes studies using novel oral formulation of Remdesivir - 21-Apr-2021 14:26
Mahindra Treo Zor crosses 1,000 sales milestone - 21-Apr-2021 13:23
Accumulate Infosys; target price of Rs 1,505: IDBI Capital - 21-Apr-2021 12:49
Accumulate ACC; target price of Rs 2,143: IDBI Capital - 21-Apr-2021 11:31
IDBI Capital maintains Hold on Nestle with target price of Rs 16,195 - 21-Apr-2021 11:19
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer